ESC 365 - Prognostic impact of SGLT2-inhibitor therapy on survival in patients with transthyretin amyloid cardiomyopathy

ESC2024 Premium Access

Prognostic impact of SGLT2-inhibitor therapy on survival in patients with transthyretin amyloid cardiomyopathy

Session: Cardiac amyloidosis: diagnosis and outcomes

Topic: Hypertrophic Cardiomyopathy

Speaker: Miss C. Toferer (Graz, AT)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Miss Christina Maria Toferer

Graz (Austria)

0 follower

7 more presentations in this session

Artificial intelligence to assist the echocardiographic identification of transthyretin cardiac amyloidosis

Speaker: Doctor V. Algalarrondo (Paris, FR)

Increased index of microcirculatory resistance, capillary rarefaction, elevated troponin levels, and their association with transthyretin amyloidosis cardiomyopathy

Speaker: Mr Y. Suiko (Miyazaki, JP)

Association of cardiac amyloidosis with cardiovascular outcomes after aortic valve replacement in patients with severe aortic stenosis: a systematic review and meta-analysis

Speaker: Doctor T. Figueira (Stony Brook, US)

Natural course and effect of tafamidis treatment in real-life octogenarians with wild-type transthyretin cardiac amyloidosis: an international multi-centre analysis.

Speaker: Doctor P. Debonnaire (Brugge, BE)

RV-PA uncoupling is a strong predictor of 3-year all-cause mortality in transthyretin amyloid cardiomyopathy.

Speaker: Doctor S. Schwarting (Munich, DE)

Access the full session

Cardiac amyloidosis: diagnosis and outcomes

Speakers: Miss C. Toferer, Doctor V. Algalarrondo, Mr Y. Suiko, Doctor T. Figueira, Doctor P. Debonnaire...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources